Sanofi SA

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

22 Jan 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: Opella reaches study milestone for Cialis

21 Jan 2025 01:00:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares – November 2024

15 Jan 2025 12:30:00 By Nasdaq GlobeNewswire

Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

13 Jan 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

09 Jan 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

23 Dec 2024 01:00:00 By Nasdaq GlobeNewswire

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors

19 Dec 2024 12:00:00 By Nasdaq GlobeNewswire

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease

17 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Press Release: Availability of the Q4 2024 Aide-mémoire

17 Dec 2024 01:30:00 By Nasdaq GlobeNewswire

Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis

13 Dec 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US

11 Dec 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients

09 Dec 2024 14:06:22 By Nasdaq GlobeNewswire

Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP

07 Dec 2024 11:30:00 By Nasdaq GlobeNewswire

Press Release: Availability of the revised financial statements for Sanofi excluding Opella

06 Dec 2024 01:30:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - October 2024

20 Nov 2024 08:11:02 By Nasdaq GlobeNewswire

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

15 Nov 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

14 Nov 2024 11:42:43 By Nasdaq GlobeNewswire

Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis

06 Nov 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance

25 Oct 2024 01:30:00 By Nasdaq GlobeNewswire

Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI

24 Oct 2024 08:00:00 By Nasdaq GlobeNewswire